Last updated: August 1, 2026
Valeant Pharmaceuticals LLC is associated with the former Valeant pharmaceutical group, which changed its corporate name to Bausch Health Companies Inc. in 2018. The operating portfolio now sits across Bausch Health, Bausch + Lomb, Salix Pharmaceuticals, Ortho Dermatologics and Solta Medical. Its market position is strongest in gastrointestinal disease, dermatology, eye care and medical aesthetics rather than broad primary-care pharmaceuticals.
The company’s commercial value is concentrated in a limited number of branded products, led by Xifaxan, while its strategic risk is concentrated in patent durability, payer pressure, debt service and generic competition. Valeant’s legacy litigation history also continues to affect how investors and counterparties evaluate its patent estate, regulatory controls and acquisition strategy.
What is Valeant Pharmaceuticals LLC’s current corporate status?
Valeant Pharmaceuticals International changed its name to Bausch Health Companies Inc. in 2018. Bausch + Lomb was separated into a standalone public company in 2022, while Bausch Health retained Salix Pharmaceuticals, Ortho Dermatologics, Solta Medical and other prescription pharmaceutical assets. [1,2]
| Entity or business |
Primary focus |
Current strategic relevance |
| Bausch Health Companies Inc. |
Specialty pharmaceuticals |
Parent company for the remaining Valeant-derived prescription portfolio |
| Salix Pharmaceuticals |
Gastroenterology |
Owner or commercial operator of Xifaxan, Trulance and related GI products |
| Ortho Dermatologics |
Medical dermatology |
Dermatology products including Bryhali, Duobrii, Jublia and Siliq |
| Bausch + Lomb |
Ophthalmology and eye care |
Separated from Bausch Health in 2022 |
| Solta Medical |
Aesthetic medical devices |
Energy-based devices and physician-administered aesthetic treatments |
The “Valeant Pharms LLC” name may appear in FDA, patent, litigation or regulatory records even where the commercial business operates under Bausch Health or a subsidiary name. Patent ownership, FDA applicant status and marketing responsibility must be checked separately for each product.
What products define Valeant’s market position?
Valeant’s strongest commercial position is in specialty medicines with high prescriber concentration, recurring treatment demand and limited direct substitutes.
Gastroenterology
Xifaxan, or rifaximin, is the central asset. The 550 mg product is approved for reducing the risk of overt hepatic encephalopathy recurrence and for irritable bowel syndrome with diarrhea. The product has been the most important branded growth driver in Bausch Health’s prescription pharmaceutical portfolio. [2,3]
Other GI products include:
- Trulance, or plecanatide, for chronic idiopathic constipation and irritable bowel syndrome with constipation.
- Apriso, or mesalamine, for ulcerative colitis maintenance therapy.
- Relistor, or methylnaltrexone, for opioid-induced constipation.
- Movantik, or naloxegol, for opioid-induced constipation.
Dermatology
The dermatology portfolio is concentrated in topical and biologic products:
- Duobrii, halobetasol propionate and tazarotene lotion, for plaque psoriasis.
- Bryhali, halobetasol propionate lotion, for plaque psoriasis.
- Jublia, efinaconazole topical solution, for onychomycosis.
- Siliq, brodalumab, for moderate-to-severe plaque psoriasis.
- Arazlo, tazarotene lotion, for acne vulgaris.
- Ortho Dermatologics also markets several legacy topical products.
Ophthalmology and medical aesthetics
The major ophthalmology business is now principally within Bausch + Lomb, not Bausch Health. Solta Medical gives the broader former Valeant group exposure to physician-administered aesthetic devices, including products used for skin resurfacing, body contouring and vascular or pigment treatments.
The separation matters competitively. Bausch Health no longer controls the full historical Valeant ophthalmology platform, while Bausch + Lomb operates as an independent public company with its own capital allocation and patent strategy. [1]
What patents protect Xifaxan and other Valeant-derived products?
Xifaxan has the most material patent estate associated with the former Valeant business. The primary technical issue is whether rifaximin patents cover the 550 mg tablets, approved indications and clinical use for hepatic encephalopathy and IBS-D.
Xifaxan patent and litigation profile
| Patent or patent family |
Subject matter |
Reported relevance |
| U.S. Patent No. 7,045,620 |
Rifaximin compositions and related use claims |
Asserted against generic challengers |
| U.S. Patent No. 8,642,573 |
Rifaximin treatment regimens and related claims |
Central to later Xifaxan litigation |
| Later U.S. patents |
Dosing, treatment and formulation claims |
Extend potential Orange Book coverage beyond earlier compound or composition patents |
In Norwich Pharmaceuticals Inc. v. Salix Pharmaceuticals Ltd., the Federal Circuit upheld findings that Norwich’s proposed generic product infringed valid Xifaxan patents. The decision limited immediate generic entry and preserved the commercial value of the listed Xifaxan patents. [4]
The litigation illustrates the structure of the Xifaxan estate. Earlier rifaximin patents may expire before later patents directed to treatment methods or approved uses. A generic applicant can challenge individual listings through a Paragraph IV certification, but the commercial launch date depends on the asserted claims, court findings, FDA approval timing and any applicable 30-month stay.
Other protected products
The former Valeant portfolio uses several patent strategies:
| Product category |
Main protection type |
Principal risk |
| Xifaxan |
Composition, formulation, dosing and method-of-use patents |
Paragraph IV challenges and induced-infringement litigation |
| Duobrii |
Combination formulation and topical delivery claims |
Formulation substitution and generic topical development |
| Bryhali |
Low-dose topical corticosteroid formulation |
ANDA litigation and therapeutic substitution |
| Siliq |
Biologic composition, manufacturing and method-of-use claims |
Biosimilar timing and biologic interchangeability |
| Jublia |
Formulation and topical delivery claims |
Generic topical competition after patent expiry |
| Trulance |
Composition, formulation and use claims |
Generic development and market exclusivity erosion |
Biologic products such as Siliq do not rely on the same abbreviated new drug application pathway as small-molecule products. A biosimilar applicant would use the Public Health Service Act pathway, with separate patent-notice and exclusivity rules. [5]
When does Valeant lose exclusivity on its major products?
No single expiry date applies to the former Valeant portfolio. Patent terms vary by product, patent family, patent-term adjustment, patent-term extension and Orange Book listing.
| Product |
FDA regulatory category |
Principal exclusivity exposure |
| Xifaxan 550 mg |
Small molecule |
Later-listed patents and litigation outcomes are more important than the earliest rifaximin patent expiry |
| Trulance |
Small molecule |
Patent estate and statutory exclusivity determine generic timing |
| Duobrii |
Small molecule topical |
Formulation and method-of-use patents are central |
| Siliq |
Biologic |
Biosimilar pathway and biologic exclusivity apply |
| Jublia |
Small molecule topical |
Formulation, device and use claims may affect entry |
| Bryhali |
Small molecule topical |
Topical formulation patents and FDA product-specific requirements |
The Orange Book remains the controlling public reference for listed patents covering approved small-molecule products. FDA’s Orange Book does not independently determine patent validity or enforceability. It records sponsor-submitted patent information and regulatory exclusivity data. [6]
What is the Orange Book status of Valeant and Bausch Health products?
Bausch Health and its subsidiaries have historically listed patents under different legal names, including Salix Pharmaceuticals, Valeant Pharmaceuticals and related applicants. The relevant search must include:
- The current NDA holder.
- Former NDA holders and successor entities.
- Product-specific trade names and active ingredients.
- Patent numbers listed in FDA’s Orange Book.
- Patent delistings, expiration updates and use-code revisions.
For Xifaxan, Orange Book review should focus on rifaximin, the 200 mg and 550 mg strengths, and the approved hepatic encephalopathy and IBS-D indications. Use codes can materially affect the scope of a Paragraph IV dispute because a generic applicant may seek approval for fewer indications through a section viii statement.
Which companies are challenging Valeant’s products?
Generic competition has focused most heavily on Xifaxan because of its revenue concentration and market size. Norwich Pharmaceuticals was a significant Xifaxan challenger and litigant. Other generic companies have pursued or may pursue products in the broader portfolio through ANDA filings, patent challenges or post-expiry launches.
The competitive field includes:
- Generic manufacturers targeting rifaximin tablets.
- Specialty generic companies developing topical dermatology products.
- Large generic manufacturers pursuing plecanatide, mesalamine or opioid-constipation products.
- Biosimilar developers assessing brodalumab’s clinical, manufacturing and market opportunity.
The commercial effect of a challenge depends on whether the applicant seeks all approved indications, whether the patent owner obtains an injunction, whether a settlement provides a licensed entry date and whether the generic launches at risk.
What patent litigation affects Valeant Pharmaceuticals?
Valeant’s historical legal exposure extends beyond product patents. The company faced investigations, securities litigation, pricing scrutiny and disputes related to specialty pharmacy practices. Those matters damaged its financing capacity and contributed to the company’s 2018 rebranding as Bausch Health. [1,7]
Product litigation has a different economic profile. The most consequential cases involve:
- Xifaxan patent validity and infringement.
- ANDA litigation against generic applicants.
- Topical formulation patents for dermatology products.
- Biologic patent and regulatory protection for Siliq.
- Manufacturing and quality-control requirements affecting generic substitution.
The Norwich-Xifaxan litigation was favorable to the branded business because it preserved patent protection against the challenged generic. Its importance is commercial rather than merely procedural: Xifaxan represents a large share of the remaining prescription pharmaceutical value.
How strong is the Valeant patent estate?
The estate is strongest where patents cover a commercially necessary formulation or a narrowly defined approved treatment population. It is weaker where protection depends on older composition patents, easily substituted topical formulations or products with multiple therapeutic alternatives.
Strength assessment
| Factor |
Assessment |
| Xifaxan patent depth |
Strong relative to the rest of the portfolio because multiple later patents and approved-use claims have been litigated |
| Dermatology formulation protection |
Moderate; topical products can face formulation-around strategies |
| Biologic protection |
Potentially strong, but biosimilar entry depends on manufacturing, clinical and interchangeability requirements |
| Geographic coverage |
Primarily U.S.-driven for revenue; foreign protection varies by country and patent family |
| Manufacturing barriers |
Meaningful for rifaximin, biologics and complex topical products, but not necessarily sufficient to prevent competition |
| Litigation capability |
Demonstrated in Xifaxan disputes, although litigation costs and debt constrain flexibility |
| Portfolio diversification |
Limited after the Bausch + Lomb separation |
Patent strength should be measured by claim scope, remaining term, validity history, regulatory relevance and the availability of non-infringing alternatives. Patent count alone is not a reliable indicator.
What generic launch scenarios exist for Xifaxan and Valeant products?
Three launch scenarios are most relevant.
Court-delayed launch
A generic receives FDA approval but cannot launch because an injunction or final judgment blocks commercialization. This was the practical outcome of the Norwich litigation while the asserted Xifaxan patents remained enforceable. [4]
Settlement-based launch
The branded company grants a license for a specified date, often with restrictions tied to patent expiration, formulation, indication or supply. Settlement terms may be confidential, and the FDA’s litigation records do not always disclose the full economic arrangement.
At-risk launch
A generic launches before final resolution of all patent claims. The company assumes damages and injunction risk if the patent owner prevails. This scenario is less attractive where the branded product has high revenue per prescription and the patent owner has a strong infringement record.
For dermatology products, authorized generics, product reformulation and therapeutic substitution can reduce the value of a patent victory even when a direct ANDA launch is delayed.
What licensing deals and partnerships affect the portfolio?
The former Valeant strategy relied heavily on acquisitions, licensing and specialty commercialization agreements rather than internal discovery. Salix and other acquired businesses brought established products with regulatory approvals, prescriber relationships and existing patent estates.
The strategic advantage is speed to revenue. The disadvantage is asset concentration and the need to service acquisition-related debt after patent-adjusted cash flows decline. Product rights may also be divided among formulation owners, NDA holders, licensors and regional distributors. That structure complicates freedom-to-operate analysis and royalty valuation.
How does Valeant compare with competing specialty pharmaceutical companies?
| Company type |
Competitive advantage versus Bausch Health |
Bausch Health response |
| Large generic manufacturers |
Lower cost and broad ANDA infrastructure |
Defend key patents and manage authorized generic risk |
| Gastroenterology specialists |
Focused clinical and commercial resources |
Protect Xifaxan and expand GI lifecycle management |
| Dermatology companies |
Stronger innovation pipelines and biologic reach |
Use topical differentiation and specialty sales channels |
| Bausch + Lomb |
Separate capital base and ophthalmology focus |
Concentrate on non-ophthalmic prescription assets |
| Biosimilar developers |
Lower-price biologic competition |
Rely on patents, manufacturing complexity and market access |
Bausch Health’s position is defensible in selected specialty markets but less diversified than the historical Valeant platform. Its performance depends more heavily on lifecycle management of established brands than on a broad pipeline of internally discovered medicines.
What revenue exposure and strategic risks matter most?
The principal financial risk is dependence on Xifaxan and other mature brands. A material decline in Xifaxan sales could affect cash generation, debt repayment and the ability to fund acquisitions or business development.
Key risks include:
- Generic entry after patent invalidation, settlement or expiration.
- Reimbursement restrictions and formulary exclusions.
- Price concessions to managed-care organizations.
- Prescription declines caused by competing therapies.
- Biosimilar competition for Siliq.
- Product recalls or manufacturing deficiencies.
- Debt refinancing and interest-rate exposure.
- Patent litigation costs.
- Loss of scale after the Bausch + Lomb separation.
Strategically, Bausch Health has an incentive to extend product lives through new indications, dosing regimens, patient populations, formulations and geographic licensing. Those tactics can produce additional patent protection, but method-of-use claims are often narrower and more vulnerable to carve-out strategies than composition claims.
Key Takeaways
- Valeant Pharmaceuticals LLC is part of the former Valeant corporate structure now operating primarily under Bausch Health and related subsidiaries.
- Xifaxan is the central asset and the most important patent and litigation focus.
- The Norwich Pharmaceuticals litigation preserved significant U.S. protection for Xifaxan against the challenged generic.
- Patent risk varies sharply by product. Xifaxan has the deepest litigated estate; topical dermatology products face greater formulation-around risk.
- Siliq is exposed to biosimilar rather than conventional ANDA competition.
- Bausch Health’s portfolio is specialty-focused but concentrated, creating substantial revenue exposure to a small group of mature branded products.
- Orange Book analysis must account for successor entities, former NDA holders, patent listings and use-code scope.
- Generic entry timing depends on patent validity, litigation outcomes, settlements, FDA approval and launch strategy.
FAQs
Is Valeant Pharmaceuticals still an active company?
The Valeant name was replaced by Bausch Health Companies Inc. in 2018. Valeant-related entities and historical legal names may still appear in patent, FDA and litigation records.
What is Valeant’s most valuable patented drug?
Xifaxan, rifaximin, is generally the most strategically important patented prescription product in the former Valeant portfolio because of its sales concentration and multiple litigated U.S. patents.
Can a generic launch Xifaxan before all patents expire?
A generic may launch only if it avoids the asserted claims, prevails in litigation, obtains a settlement license, or accepts the risk of an at-risk launch. FDA approval alone does not eliminate enforceable patent barriers.
Is Siliq exposed to biosimilar competition?
Yes. Siliq is a biologic and would be challenged through the biosimilar pathway rather than the conventional ANDA pathway. Patent, regulatory exclusivity and manufacturing issues all affect entry timing.
Does the Orange Book list every Valeant patent?
No. The Orange Book lists patents submitted for approved small-molecule products under FDA rules. It does not list every patent owned by Valeant-related entities, including many manufacturing, foreign, formulation or non-approved-use patents.
References
-
Bausch Health Companies Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
-
Bausch Health Companies Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: Xifaxan (rifaximin) prescribing information and approval history.
-
United States Court of Appeals for the Federal Circuit. (2023). Norwich Pharmaceuticals Inc. v. Salix Pharmaceuticals Ltd., 2023 WL 4399621.
-
U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable products.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
-
U.S. Securities and Exchange Commission. (2018). Bausch Health Companies Inc. corporate name change and regulatory filings.
